J&J submits MAA for telaprevir in HCV
This article was originally published in Scrip
Hoping to take some of the focus away from manufacturing problems that it has faced in recent times, Johnson & Johnson has announced that its Janssen-Cilag International subsidiary has submitted a marketing authorization application to the European Medicines Agency (EMA) for telaprevir, an investigational, oral direct-acting anti-viral to treat chronic genotype 1 hepatitis C virus (HCV).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.